Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505414 | 0.84 | HPGD (0.47) | HTR2CALDH1A1KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL12209850 | 0.83 | NPC1 (0.45) | HTR2CKDM4ERXFP1NPC1SMN1; SMN2 | |
| SCHEMBL6503762 | 0.82 | SHMT1 (0.56) | ALDH1A1KDM4ENPC1SMN1; SMN2RAB9A | |
| SCHEMBL6495873 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4ERXFP1NPC1SMN1; SMN2 | |
| SCHEMBL12209856 | 0.80 | HTR2C (0.39) | HTR2CALDH1A1KDM4ERXFP1NPC1 | |
| SCHEMBL6496262 | 0.79 | PTGDR2 (0.49) | ALDH1A1KDM4ENPC1SMN1; SMN2RAB9A | |
| SCHEMBL3995172 | 0.79 | RARA (0.60) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL3418888 | 0.79 | SMN1; SMN2 (0.65) | HTR2CALDH1A1KDM4ERXFP1NPC1 | |
| SCHEMBL2095721 | 0.77 | ALDH1A1 (0.51) | ALDH1A1KDM4ERXFP1NPC1SMN1; SMN2 | |
| SCHEMBL269670 | 0.76 | KMT2A (0.46) | ALDH1A1KDM4ERXFP1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931323-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9505746-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | GENENTECH, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-9328106-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8435976-B2 | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
| US-6884821-B1 | Carboxylic acid derivatives and drugs containing the same | EISAI CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1216980-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | HTR2C 2078/4885ALDH1A1 1703/4885KDM4E 1733/4885 |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | HTR2C 2078/4885ALDH1A1 1703/4885KDM4E 1733/4885 |
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | PIM1, PIM2, PIM3 | HTR2C 2279/4885ALDH1A1 3026/4885KDM4E 618/4885 |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | HTR2C 2078/4885ALDH1A1 1703/4885KDM4E 1733/4885 |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | HTR2C 2657/4885ALDH1A1 1462/4885KDM4E 1695/4885 |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | HTR2C 2831/4885ALDH1A1 1066/4885KDM4E 309/4885 |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | HTR2C 2657/4885ALDH1A1 1462/4885KDM4E 1695/4885 |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | HTR2C 2279/4885ALDH1A1 3026/4885KDM4E 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.